Commonwealth of Pennsylvania Public School Empls Retrmt SYS Sells 261 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Commonwealth of Pennsylvania Public School Empls Retrmt SYS cut its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 1.9% during the fourth quarter, Holdings Channel.com reports. The fund owned 13,352 shares of the specialty pharmaceutical company’s stock after selling 261 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Jazz Pharmaceuticals were worth $1,644,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the business. CIBC Asset Management Inc grew its position in shares of Jazz Pharmaceuticals by 5.2% during the fourth quarter. CIBC Asset Management Inc now owns 1,972 shares of the specialty pharmaceutical company’s stock worth $243,000 after purchasing an additional 97 shares in the last quarter. UMB Bank n.a. boosted its stake in Jazz Pharmaceuticals by 70.9% in the 4th quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock worth $38,000 after purchasing an additional 129 shares during the period. Jones Financial Companies Lllp grew its holdings in Jazz Pharmaceuticals by 75.1% during the 4th quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company’s stock valued at $37,000 after buying an additional 130 shares in the last quarter. Waterfront Wealth Inc. raised its position in shares of Jazz Pharmaceuticals by 1.4% during the fourth quarter. Waterfront Wealth Inc. now owns 9,675 shares of the specialty pharmaceutical company’s stock valued at $1,191,000 after buying an additional 137 shares during the last quarter. Finally, Ellsworth Advisors LLC lifted its holdings in shares of Jazz Pharmaceuticals by 0.4% in the fourth quarter. Ellsworth Advisors LLC now owns 37,962 shares of the specialty pharmaceutical company’s stock worth $4,675,000 after buying an additional 149 shares in the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

JAZZ has been the subject of several research analyst reports. Cantor Fitzgerald cut shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and raised their target price for the company from $140.00 to $150.00 in a research note on Wednesday, February 26th. Needham & Company LLC restated a “buy” rating and set a $210.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 5th. Truist Financial boosted their target price on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a research report on Thursday, March 6th. Piper Sandler reissued an “overweight” rating and set a $176.00 price target (up from $163.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, February 26th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $183.00 price objective (up from $175.00) on shares of Jazz Pharmaceuticals in a report on Friday, March 7th. One research analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $187.71.

Insider Buying and Selling

In related news, CAO Patricia Carr sold 1,140 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $137.81, for a total transaction of $157,103.40. Following the completion of the sale, the chief accounting officer now directly owns 7,012 shares of the company’s stock, valued at approximately $966,323.72. This trade represents a 13.98 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CMO Robert Iannone sold 2,403 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $138.41, for a total value of $332,599.23. Following the completion of the sale, the chief marketing officer now owns 79,621 shares in the company, valued at approximately $11,020,342.61. The trade was a 2.93 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 28,736 shares of company stock valued at $4,022,825. Company insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Stock Down 4.8 %

NASDAQ JAZZ opened at $135.25 on Wednesday. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $148.06. The firm has a market capitalization of $8.21 billion, a price-to-earnings ratio of 19.05, a PEG ratio of 1.04 and a beta of 0.44. The company has a fifty day moving average of $132.04 and a two-hundred day moving average of $122.23.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.